Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096381 · ClinicalTrials.gov registry record
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 8
- Enrollment target
NCT01096381: Clinical Trial study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT01096381 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096381 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure. PURPOSE: This phase I trial is studying potential biomarkers for bevacizumab-induced high blood pressure in patients with malignant solid tumors, including breast cancer, colorectal cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-08 |
Why NCT01096381 stopped before completion
NCT01096381 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01096381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01096381 about?
NCT01096381 is a clinical study titled "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor". RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure. PURPOSE: This phase I trial is studying potential biomarkers for bevac...
What is the current status of trial NCT01096381?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2010-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01096381?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01096381?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia